The last patient with advanced hepatocellular carcinoma was enrolled on the phase 2 HEPANOVA trial, which is investigating the combination of Tumor Treating Fields and sorafenib. The combination showed safety and tolerability for patients in an interim analysis.
"Since 2008, 1748 community oncology clinics and/or practices have closed, been acquired by hospitals, undergone corporate mergers, or reported financial difficulties."
"Taletrectinib is a promising oral tyrosine kinase inhibitor highly selective for ROS1/NTRK mutations with potent activity against ROS1 resistance mutations like G2032R."
"In the case of sarcomas treated with the current standard of care, doxorubicin, tumors may be initially responsive in their primary location, but become unresponsive after metastasis to the lungs, which eventually becomes the most likely cause of patients' death."
Oncology practices like Northwest Medical Specialties are looking for ways to improve their patient care and are willing to transform their practice to do so.
“RASMT associated with adverse phenotypic features were concluded to be an independent predictor of inferior overall survival and were associated with a higher cumulative incidence of leukemic transformation."
“Community-based clinical trials come with many benefits. They enable patients to be matched with potentially life-saving research while staying within the comfort and familiarity of their local oncologist’s office.”
We believe that lenvatinib could be a standard second-line treatment option for patients with thymic carcinoma.”
The NCCN guidelines recommend biomarker testing as a part of the pathologic evaluation for patients with non-squamous advanced NSCLC and NCC set out to determine how these guidelines decrease the incidence of mortality.
In a subgroup analysis of cohort 1 of the phase 2 ZENITH20 study, patients with previously treated non-small cell lung cancer and EGFR exon 20 insertions demonstrated clinical activity when receiving poziotinib, including those with central nervous system metastatic disease, which was not impacted by prior lines of therapy.
"..These findings may be susceptible to selection bias since patients with more aggressive disease may be more likely to start dabrafenib and trametinib in the first line."
“The data demonstrated deepening clinical responses with cemiplimab over time. Furthermore, duration of response and overall survival [OS] are considerably longer with cemiplimab than what has previously been recorded with other agents.”
Favorable activity and safety findings were demonstrated with the combination of CC-92480 plus dexamethasone as treatment of patients with heavily pretreated relapsed or refractory multiple myeloma in an ongoing study, according to a presentation from the 2020 American Society of Clinical Oncology Virtual Scientific Program.
Cabazitaxel demonstrated better patients-reported outcomes compared with either abiraterone or enzalutamide in men with metastatic castration-resistant prostate cancer.
"Over the last 12 years, an average of 9 practices per month have closed, been acquired by a hospital, or merged. These are troubling trends and dangerous for patients battling cancer...”
As the breast cancer setting quickly changes with each advancement, physicians who care for these patients will need to know how to apply these emerging treatments to the standards of care in their practice.
In an interview with Targeted Oncology, Timothy D. Moore, MD, discussed how his institution is handling concerns regarding coronavirus disease 2019 and what he is seeing with patients and cancer programs.
Elderly patients with advanced prostate cancer should be evaluated for preexisting cardiovascular diseases before taking oral androgen signaling inhibitors by a multidisciplinary team, includ­ing a cardiologist, according to a recent retro­spective study. Investigators at Thomas Jeffer­son University in Philadelphia, Pennsylvania, demonstrated that after receiving abiraterone acetate or enzalutamide, these patients had higher rates of short-term mortality than similar patients without CVDs.
In an interview with Targeted Oncology, Randall A. Oyer, MD, discussed how his institution is handling the pandemic while still accommodating patients who are already on clinical trials and making sure everyone stays safe.
As the new coronavirus disease 2019 creates problems internationally, health-wise and economically, it is also becoming a cause for concern throughout the oncology community.
Patients with metastatic renal cell carcinoma in a real-world cohort of a retrospective analysis demonstrated positive activity and a favorable safety profile when receiving frontline tivozanib.
To help clinicians cope with an increasing number of geriatric patients with cancer, the Association of Community Cancer Centers is addressing this problem with a 2-pronged approach that focuses on the delivery of care and diagnostic assessment.
In the CheckMate 025 trial, nivolumab remained superior to everolimus in terms of efficacy and safety in patients with advanced renal cell carcinoma at more than 5 years minimum follow-up and had continued responses in 28 percent of patients, according to a presentation at the 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Pepinemab plus avelumab has shown initial signals of antitumor activity and is well tolerated in patients with advanced non–small cell lung cancer, according to an interim analysis of the CLASSICAL-Lung phase Ib/II clinical trial presented at the 2020 American Society of Clinical Oncology-Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium in Orlando, Florida.
An open, multicenter phase II trial of extend-release onapristone in patients with progesterone receptor–positive recurrent granulosa cell ovarian cancer, low-grade serous ovarian/primary peritoneal cancer, or endometroid endometrial cancer will demonstrate if the investigational drug will shrink or stop the cancer.
Patients with aggressive meningiomas presented with clinical and radiological activity when receiving a combination of everolimus and octreotide in the single-arm phase II CEVOREM trial.<br />
Although groundbreaking research findings are met with much fanfare during large medical conferences, their practical application to the community oncology clinic may not always be immediately clear.
For patients with non–small cell lung cancer, having a body mass index ≥30 at baseline could be independently associated with an improvement in overall survival with atezolizumab and could be considered a stratification factor in immune checkpoint inhibitor trials, according to a study published in JAMA Oncology.
The present and future benefits of telehealth in oncology can be observed through Tahoe For­est Cancer Center and its affiliation with the UC Davis Cancer Center, use of other remote clinics, and participation in virtual tumor boards. Even though there are roadblocks to telehealth reaching more locations and more patients, the potential benefit warrants the time needed to get over those hurdles.
Selpercatinib will be compared with the standard of care in the first ever phase III clinical trial in patients with advanced or metastatic treatment-naïve <em>RET</em> fusion-positive non–small cell lung cancer, according to a press release from Eli Lilly and Company.